congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Oral
T-DXd
ESMO 2024 | September 13-17, 2024
A multicentre, randomized, double-blind, placebo-controlled study of olanzapine-based triplet antiemetic therapy for prevention of delayed and persistent nausea and vomiting induced by trastuzumab deruxtecan in patients with metastatic breast cancer: ERICA study (WJOG14320B)
Poster
DS-1471
ESMO 2024 | September 13-17, 2024
A phase 1, first-in-human study of DS-1471 in patients with advanced/metastatic solid tumors
Poster
Other/Multi
ESMO 2024 | September 13-17, 2024
Claudin-6 expression in primary and recurrant epithelial ovarian cancer: A potential therapeutic target for high-grade serous ovarian cancer
Poster
Dato-DXd
ESMO 2024 | September 13-17, 2024
Dato-DXd vs docetaxel in patients with advanced nonsquamous non-small cell lung cancer with brain metastases: Results from TROPION-Lung01
Mini-Oral
Dato-DXd
ESMO 2024 | September 13-17, 2024
Datopotamab deruxtecan (Dato-DXd) in patients with ovarian or endometrial cancer: Results from the phase 2 TROPION-PanTumor03 study
Oral
T-DXd
ESMO 2024 | September 13-17, 2024
Effects of trastuzumab deruxtecan vs choice of chemotherapy on patient-reported outcomes in hormone receptor–positive, HER2-low or HER2-ultralow metastatic breast cancer: Results from DESTINY-Breast06
Oral
HER3-DXd
ESMO 2024 | September 13-17, 2024
Efficacy, safety and biomarker analysis of ICARUS-BREAST01: A phase 2 study of patritumab deruxtecan (HER3-DXd) in patients with HR+/HER2- advanced breast cancer
Poster
T-DXd
ESMO 2024 | September 13-17, 2024
Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician’s choice in HER2-low, hormone receptor–positive metastatic breast cancer in DESTINY-Breast04
Poster
Dato-DXd
ESMO 2024 | September 13-17, 2024
Exposure-adjusted incidence rates (EAIRs) of adverse events from the TROPION-Breast01 study of datopotamab deruxtecan (Dato-DXd) vs investigator’s choice of chemotherapy in patients with pretreated, inoperable/metastatic HR+/HER2– breast cancer
Poster
T-DXd
ESMO 2024 | September 13-17, 2024
HER2 testing in multiple solid tumors: Concordance between 3 scoring algorithms
Pages:
1 2